MSB 2.10% $1.17 mesoblast limited

USD573M in retained losses and a less than great 2020!. 2021 a year that cannot get worse, page-30

  1. 12,398 Posts.
    lightbulb Created with Sketch. 3370
    I'm not too sure what else you would expect.

    The FDA process is long, arduous and costly.
    Of course a company should get success in the earlier trials to progress it from pre-clinical, to P1, to P2 and then P3 trials.
    When you multiply that by the indications that Mesoblast has, yes there's a lot of early success.

    The burden of bringing a paradigm shift in medical treatment is now a stumbling block to get to the actual FDA approval.
    But, that's where we are at.
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.